RHHBY - Roche's Phesgo along with Halozyme's ENHANZE technology OK'd in Europe in breast cancer

The European Commission ((EC)) has approved Roche's (RHHBY) Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with Halozyme Therapeutics' (HALO) ENHANZE technology, administered by subcutaneous injection for the treatment of patients with early and metastatic HER2-positive breast cancer.Phesgo has the potential to reduce administration time, as well as other costs associated with treatment, such as time spent in the infusion chair and drug preparation.

For further details see:

Roche's Phesgo along with Halozyme's ENHANZE technology OK'd in Europe in breast cancer